Car-T immunotherapy treatments have become an incredibly hot area of cancer research. These treatments hold a lot of potential because the idea is to activate the patients’ own cells in order to help combat cancer. These treatments seemed to be preferable to chemotherapy. However, a recent clinical hold was issued against one of the main Car-T immunotherapy companies Juno Therapeutics (NASDAQ:JUNO), and while the company claims to have resolved the issue I still remain skeptical.
